TrialLeukemia2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
A Larocca et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled ittrialcites it